All In MedTech

FDA Clearance Tracker · P180008

t:slim X2 Insulin Pump with Basal-IQ Technology

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jun 21, 2018 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 21, 2018

Approved

Time to decision

115 days

Received Feb 26, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P180008
Device name
t:slim X2 Insulin Pump with Basal-IQ Technology
Applicant location
San Diego, CA
Received
Feb 26, 2018
Decided
Jun 21, 2018
Decision
Approved
Supplements
6 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OZO

FDA's approval statement

As written in FDA's record.

Approval for the use of the t:slim X2 Insulin Pump with Basal-IQ Technology. This device is indicated as follows:The t:slim X2 Insulin Pump with Basal-IQ Technology (the System) consists of the t:slim X2 Insulin Pump which contains the Basal-IQ technology, and a continuous glucose monitor (CGM). Compatible CGMs include the Dexcom G5 Mobile CGM and integrated continuous glucose monitors (iCGMs) that are listed in the labeling for this device.The t:slim X2 Insulin Pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 Insulin Pump can be used solely for continuous insulin delivery and as part of the t:slim X2 Insulin Pump with Basal-IQ Technology System.When the System is used with the Dexcom G5 Mobile CGM or a compatible iCGM, the Basal-IQ Technology can be used to suspend insulin delivery based on CGM sensor readings. The Dexcom G5 Mobile CGM Continuous Glucose Monitoring System (Dexcom G5) is indicated for the management of diabetes in persons age 2 years and older. The Dexcom G5 is designed to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the System results should be based on the trends and patterns seen with several sequential readings over time. The Dexcom G5 also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. The Dexcom G5 is intended for single patient use and requires a prescription.The System is indicated for use in individuals 6 years of age and greater.The System is intended for single patient use and requires a prescription.The System is indicated for use with NovoLog or Humalog U-100 insulin.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OZO. The earliest in FDA's data is P120010, decided Sep 26, 2013.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Tandem Diabetes Care, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.